Amrutanjan Health (AMRUTANJAN) | Financial Analysis & Statements
Amrutanjan Health Care Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
940.5M
Gross Profit
446.6M
47.48%
Operating Income
69.2M
7.35%
Net Income
83.1M
8.84%
EPS (Diluted)
₹2.87
Balance Sheet Metrics
Total Assets
4.3B
Total Liabilities
902.9M
Shareholders Equity
3.4B
Debt to Equity
0.26
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Amrutanjan Health Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.5B | 4.2B | 3.8B | 4.0B | 3.3B |
| Cost of Goods Sold | 2.2B | 2.1B | 1.8B | 1.8B | 1.4B |
| Gross Profit | 2.3B | 2.1B | 2.0B | 2.2B | 1.9B |
| Gross Margin % | 50.5% | 49.6% | 51.9% | 55.4% | 57.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 820.4M | 786.9M | 771.7M | 756.6M | 580.3M |
| Other Operating Expenses | 205.2M | 222.6M | 185.8M | 96.6M | 52.0M |
| Total Operating Expenses | 1.0B | 1.0B | 957.4M | 853.3M | 632.3M |
| Operating Income | 535.7M | 480.2M | 420.6M | 819.7M | 795.0M |
| Operating Margin % | 11.9% | 11.4% | 11.1% | 20.3% | 23.9% |
| Non-Operating Items | |||||
| Interest Income | 160.5M | 148.0M | 117.8M | 111.7M | 93.9M |
| Interest Expense | 2.2M | 1.6M | 771.0K | 4.8M | 5.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 691.3M | 619.5M | 536.5M | 905.8M | 819.0M |
| Income Tax | 183.0M | 169.7M | 138.1M | 233.9M | 207.1M |
| Effective Tax Rate % | 26.5% | 27.4% | 25.7% | 25.8% | 25.3% |
| Net Income | 508.3M | 449.7M | 398.3M | 671.9M | 611.9M |
| Net Margin % | 11.3% | 10.7% | 10.5% | 16.6% | 18.4% |
| Key Metrics | |||||
| EBITDA | 760.8M | 689.2M | 591.8M | 970.3M | 939.7M |
| EPS (Basic) | ₹17.58 | ₹15.50 | ₹13.65 | ₹23.00 | ₹20.94 |
| EPS (Diluted) | ₹17.58 | ₹15.50 | ₹13.63 | ₹22.98 | ₹20.93 |
| Basic Shares Outstanding | 28910630 | 29019920 | 29178398 | 29207609 | 29221922 |
| Diluted Shares Outstanding | 28910630 | 29019920 | 29178398 | 29207609 | 29221922 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Amrutanjan Health Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 803.8M | 257.6M | 675.6M | 834.8M | 1.3B |
| Short-term Investments | 1.1B | 1.8B | 1.2B | 1.2B | 446.4M |
| Accounts Receivable | 558.2M | 478.9M | 330.2M | 382.6M | 176.6M |
| Inventory | 272.6M | 289.0M | 288.3M | 260.0M | 174.6M |
| Other Current Assets | 82.6M | 75.7M | 51.4M | 50.5M | 38.2M |
| Total Current Assets | 2.9B | 3.0B | 2.6B | 2.7B | 2.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 41.9M | 27.2M | 24.0M | 17.7M | 7.4M |
| Goodwill | 17.3M | 23.8M | 24.8M | 23.2M | 15.1M |
| Intangible Assets | 17.3M | 23.8M | 24.8M | 23.2M | 15.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 176.5M | 17.1M | 15.4M | 19.2M | -100.0K |
| Total Non-Current Assets | 1.3B | 711.9M | 1.0B | 752.2M | 513.7M |
| Total Assets | 4.2B | 3.7B | 3.6B | 3.5B | 2.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 690.4M | 558.6M | 474.4M | 604.5M | 406.7M |
| Short-term Debt | 4.0M | 3.3M | 5.1M | 5.7M | 6.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 94.5M | 84.0M | 78.5M | 65.0M | 48.6M |
| Total Current Liabilities | 845.8M | 699.2M | 630.1M | 774.7M | 521.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 16.8M | 14.0M | 4.0M | 3.1M | 7.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 101.9M | 84.6M | 83.1M | 72.7M | 66.0M |
| Total Liabilities | 947.7M | 783.8M | 713.2M | 847.4M | 587.1M |
| Equity | |||||
| Common Stock | 28.9M | 28.9M | 29.2M | 29.2M | 29.2M |
| Retained Earnings | 2.7B | 2.4B | 2.4B | 2.1B | 1.6B |
| Treasury Stock | 10.6M | 16.2M | 44.6M | 45.0M | 9.6M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.3B | 2.9B | 2.9B | 2.7B | 2.2B |
| Key Metrics | |||||
| Total Debt | 20.8M | 17.3M | 9.1M | 8.8M | 13.4M |
| Working Capital | 2.1B | 2.3B | 2.0B | 2.0B | 1.7B |
Balance Sheet Composition
Amrutanjan Health Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 691.3M | 619.5M | 536.5M | 905.8M | 819.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 11.4M | 2.2M | 4.4M | -113.0K | 6.2M |
| Working Capital Changes | -62.4M | -191.9M | 8.4M | -287.9M | 209.6M |
| Operating Cash Flow | 482.1M | 282.8M | 432.2M | 510.9M | 945.9M |
| Investing Activities | |||||
| Capital Expenditures | -355.5M | -64.6M | -88.8M | -234.6M | -18.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -114.6M | - | -123.2M | -302.1M | -915.3M |
| Investment Sales | 5.0K | 115.0M | 75.0M | 48.2M | 0 |
| Investing Cash Flow | -470.1M | 50.4M | -137.1M | -488.5M | -934.0M |
| Financing Activities | |||||
| Share Repurchases | 0 | -288.0M | 0 | - | -9.6M |
| Dividends Paid | -132.7M | -133.9M | -144.1M | -124.8M | -57.8M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -130.3M | -477.1M | -144.1M | -160.1M | -86.8M |
| Free Cash Flow | 153.5M | 211.9M | 112.5M | 287.3M | 889.1M |
| Net Change in Cash | -118.4M | -143.8M | 151.0M | -137.6M | -74.8M |
Cash Flow Trend
Amrutanjan Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
29.33
Price to Book
4.87
Price to Sales
3.41
PEG Ratio
27.90
Profitability Ratios
Profit Margin
11.65%
Operating Margin
16.69%
Return on Equity
15.56%
Return on Assets
12.06%
Financial Health
Current Ratio
3.69
Debt to Equity
0.57
Beta
0.34
Per Share Data
EPS (TTM)
₹19.66
Book Value per Share
₹118.34
Revenue per Share
₹168.93
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMRUTANJAN | 16.7B | 29.33 | 4.87 | 15.56% | 11.65% | 0.57 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





